{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:36:58Z","timestamp":1791351418769,"version":"4.3.1"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T00:00:00Z","timestamp":1479340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0005125","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T13:26:07Z","timestamp":1479389167000},"page":"e0005125","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model"],"prefix":"10.1371","volume":"10","author":[{"given":"Fr\u00e9d\u00e9ric-Antoine","family":"Dauchy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Bonhivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Landrein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Dacheux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierrette","family":"Courtois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lauruol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Daulou\u00e8de","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Vincendeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick R.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,11,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1469-0691.2011.03536.x","article-title":"Sleeping sickness","volume":"17","author":"D Malvy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"G Priotto","year":"2009","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo","volume":"56","author":"E Alirol","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1126\/science.6775372","article-title":"Polyamine metabolism: a potential therapeutic target in trypanosomes","volume":"210","author":"CJ Bacchi","year":"1980","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/jama.1991.03460100029008","article-title":"From the Food and Drug Administration","volume":"265","author":"SL Nightingale","year":"1991","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0035-9203(90)90125-X","article-title":"Future prospects for the chemotherapy of human trypanosomiasis. 2. Combination chemotherapy and African trypanosomiasis","volume":"84","author":"FW Jennings","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"13088","DOI":"10.1074\/jbc.M111.230847","article-title":"Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites","volume":"286","author":"BS Hall","year":"2011","journal-title":"J Biol Chem"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1086\/656917","article-title":"Tolerance and safety of nifurtimox in patients with chronic chagas disease","volume":"51","author":"Y Jackson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2174\/156802611796575902","article-title":"Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis","volume":"11","author":"GI Lepesheva","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"642502","DOI":"10.1155\/2009\/642502","article-title":"Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs","volume":"2009","author":"W de Souza","year":"2009","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e0003588","DOI":"10.1371\/journal.pntd.0003588","article-title":"Targeting Ergosterol biosynthesis in Leishmania donovani: essentiality of sterol 14 alpha-demethylase","volume":"9","author":"LI McCall","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.85.18.6753","article-title":"Receptors for the host low density lipoproteins on the hemoflagellate Trypanosoma brucei: purification and involvement in the growth of the parasite","volume":"85","author":"I Coppens","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1194\/jlr.M600404-JLR200","article-title":"Cholesterol import fails to prevent catalyst-based inhibition of ergosterol synthesis and cell proliferation of Trypanosoma brucei","volume":"48","author":"W Zhou","year":"2007","journal-title":"J Lipid Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/BJ20111849","article-title":"Novel sterol metabolic network of Trypanosoma brucei procyclic and bloodstream forms","volume":"443","author":"CR Nes","year":"2012","journal-title":"Biochem J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0166-6851(02)00280-3","article-title":"Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa","volume":"126","author":"CW Roberts","year":"2003","journal-title":"Mol Biochem Parasitol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1101\/gr.115089.110","article-title":"High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome","volume":"21","author":"S Alsford","year":"2011","journal-title":"Genome Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ijpara.2012.07.012","article-title":"Endogenous sterol biosynthesis is important for mitochondrial function and cell morphology in procyclic forms of Trypanosoma brucei","volume":"42","author":"G Perez-Moreno","year":"2012","journal-title":"Int J Parasitol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.chembiol.2007.10.011","article-title":"Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth","volume":"14","author":"GI Lepesheva","year":"2007","journal-title":"Chem Biol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"II Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"TJ Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"OA Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"AJ Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: a broad-spectrum triazole antifungal","volume":"5","author":"HA Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/13543784.15.6.579","article-title":"Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations","volume":"15","author":"G Aperis","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1074\/jbc.M109.067470","article-title":"Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections","volume":"285","author":"GI Lepesheva","year":"2010","journal-title":"J Biol Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1371\/journal.pntd.0000651","article-title":"Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole","volume":"4","author":"CK Chen","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e83247","DOI":"10.1371\/journal.pone.0083247","article-title":"In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis","volume":"8","author":"ST de Macedo-Silva","year":"2013","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1128\/AAC.43.12.2910","article-title":"Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases","volume":"43","author":"HM Al-Abdely","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AAC.44.1.150-155.2000","article-title":"Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts","volume":"44","author":"J Molina","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0166-6851(99)00002-X","article-title":"A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei","volume":"99","author":"E Wirtz","year":"1999","journal-title":"Mol Biochem Parasitol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2307\/3282883","article-title":"Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers","volume":"75","author":"H Hirumi","year":"1989","journal-title":"J Parasitol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0014-4894(92)90220-5","article-title":"Nitric oxide-mediated cytostatic activity on Trypanosoma brucei gambiense and Trypanosoma brucei brucei","volume":"75","author":"P Vincendeau","year":"1992","journal-title":"Exp Parasitol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2180-10-20","article-title":"Exocytosis and protein secretion in Trypanosoma","volume":"10","author":"A Geiger","year":"2010","journal-title":"BMC Microbiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1172\/JCI22104","article-title":"Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei penetration of the blood-brain barrier","volume":"114","author":"W Masocha","year":"2004","journal-title":"J Clin Invest"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1128\/AAC.50.5.1798-1804.2006","article-title":"Minocycline impedes African trypanosome invasion of the brain in a murine model","volume":"50","author":"W Masocha","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4269\/ajtmh.1994.50.13","article-title":"Identification of Trypanosoma brucei gambiense group I by a specific kinetoplast DNA probe","volume":"50","author":"F Mathieu-Daude","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1128\/MCB.10.6.3036","article-title":"Transcription of the procyclic acidic repetitive protein genes of Trypanosoma brucei","volume":"10","author":"CE Clayton","year":"1990","journal-title":"Mol Cell Biol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0166-6851(99)00171-1","article-title":"Characterization of Trypanozoon isolates using a repeated coding sequence and microsatellite markers","volume":"105","author":"N Biteau","year":"2000","journal-title":"Mol Biochem Parasitol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1371\/journal.pntd.0000509","article-title":"Murine Models for Trypanosoma brucei gambiense disease progression\u2014from silent to chronic infections and early brain tropism","volume":"3","author":"C Giroud","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"14687","DOI":"10.1073\/pnas.95.25.14687","article-title":"Double-stranded RNA induces mRNA degradation in Trypanosoma brucei","volume":"95","author":"H Ngo","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1126\/science.7761835","article-title":"Inducible gene expression in trypanosomes mediated by a prokaryotic repressor","volume":"268","author":"E Wirtz","year":"1995","journal-title":"Science"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0166-6851(96)02815-0","article-title":"Vectors for inducible expression of toxic gene products in bloodstream and procyclic Trypanosoma brucei","volume":"85","author":"S Biebinger","year":"1997","journal-title":"Mol Biochem Parasitol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"D457","DOI":"10.1093\/nar\/gkp851","article-title":"TriTrypDB: a functional genomic resource for the Trypanosomatidae","volume":"38","author":"M Aslett","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"17580","DOI":"10.1074\/jbc.M200873200","article-title":"Trypanosoma brucei FLA1 is required for flagellum attachment and cytokinesis","volume":"277","author":"DJ LaCount","year":"2002","journal-title":"J Biol Chem"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.molbiopara.2010.09.002","article-title":"Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters","volume":"175","author":"G Schumann Burkard","year":"2011","journal-title":"Mol Biochem Parasitol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0014-4894(70)90120-7","article-title":"Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose","volume":"28","author":"SM Lanham","year":"1970","journal-title":"Exp Parasitol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0020-7519(80)90025-9","article-title":"In vitro growth of Trypanosoma musculi in cell-free medium conditioned by rodent macrophages and mercaptoethanol","volume":"10","author":"JW Albright","year":"1980","journal-title":"Int J Parasitol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00436-012-3183-4","article-title":"Antiprotozoal activity of ferroquine","volume":"112","author":"S Pomel","year":"2013","journal-title":"Parasitol Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e1000939","DOI":"10.1371\/journal.ppat.1000939","article-title":"Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs","volume":"6","author":"YQ Zhang","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"34205","DOI":"10.1074\/jbc.M113.518993","article-title":"Trypanosoma brucei vacuolar transporter chaperone 4 (TbVtc4) is an acidocalcisome polyphosphate kinase required for in vivo infection","volume":"288","author":"N Lander","year":"2013","journal-title":"J Biol Chem"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.38.3.563","article-title":"Combination chemotherapy of drug-resistant Trypanosoma brucei rhodesiense infections in mice using DL-alpha-difluoromethylornithine and standard trypanocides","volume":"38","author":"CJ Bacchi","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0014-4894(76)90110-7","article-title":"Trypanosoma brucei: a rapid "matching" method for estimating the host's parasitemia","volume":"40","author":"WJ Herbert","year":"1976","journal-title":"Exp Parasitol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbagen.2015.10.015","article-title":"Ligand tunnels in T. brucei and human CYP51: Insights for parasite-specific drug design","volume":"1860","author":"X Yu","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejmech.2016.02.028","article-title":"In vitro screening of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives as antiprotozoal agents and docking studies on Trypanosoma cruzi CYP51","volume":"113","author":"D De Vita","year":"2016","journal-title":"Eur J Med Chem"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/35300","article-title":"Paraflagellar rod is vital for trypanosome motility","volume":"391","author":"P Bastin","year":"1998","journal-title":"Nature"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-0711-5-25","article-title":"In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains","volume":"5","author":"G Miranda-Novales","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbagen.2006.07.018","article-title":"Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms","volume":"1770","author":"GI Lepesheva","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"e1004427","DOI":"10.1371\/journal.ppat.1004427","article-title":"Sterol biosynthesis is required for heat resistance but not extracellular survival in leishmania","volume":"10","author":"W Xu","year":"2014","journal-title":"PLoS Pathog"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molbiopara.2005.09.002","article-title":"A vector series for rapid PCR-mediated C-terminal in situ tagging of Trypanosoma brucei genes","volume":"145","author":"M Oberholzer","year":"2006","journal-title":"Mol Biochem Parasitol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1128\/AAC.00205-07","article-title":"Quinuclidine derivatives as potential antiparasitics","volume":"51","author":"SB Cammerer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.chembiol.2015.08.017","article-title":"Fluorinated Sterols Are Suicide Inhibitors of Ergosterol Biosynthesis and Growth in Trypanosoma brucei","volume":"22","author":"DJ Leaver","year":"2015","journal-title":"Chem Biol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1194\/jlr.M021865","article-title":"Structural complex of sterol 14alpha-demethylase (CYP51) with 14alpha-methylenecyclopropyl-Delta7-24, 25-dihydrolanosterol","volume":"53","author":"TY Hargrove","year":"2012","journal-title":"J Lipid Res"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1021\/jm801643b","article-title":"Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase","volume":"52","author":"ME Konkle","year":"2009","journal-title":"J Med Chem"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"V Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/AAC.48.10.3690-3696.2004","article-title":"Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds","volume":"48","author":"HK Munayyer","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jac\/dku393","article-title":"A sensitive and reproducible in vivo imaging mouse model for evaluation of drugs against late-stage human African trypanosomiasis","volume":"70","author":"H Burrell-Saward","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"e2384","DOI":"10.1371\/journal.pntd.0002384","article-title":"In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis","volume":"7","author":"E Myburgh","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/myc.12023","article-title":"Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis","volume":"56","author":"WJ Heinz","year":"2013","journal-title":"Mycoses"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1345\/aph.1R775","article-title":"Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer","volume":"47","author":"VA Bernardo","year":"2013","journal-title":"Ann Pharmacother"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","article-title":"Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants","volume":"26","author":"AH Saad","year":"2006","journal-title":"Pharmacotherapy"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"F Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"G Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1128\/AAC.00496-15","article-title":"Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension","volume":"59","author":"U Durani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/AAC.05000-14","article-title":"Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation","volume":"59","author":"WM Kersemaekers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1128\/AAC.03252-14","article-title":"Posaconazole concentrations in human tissues after allogeneic stem cell transplantation","volume":"58","author":"O Blennow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/jpet.112.201541","article-title":"Experimental models of disseminated scedosporiosis with cerebral involvement","volume":"345","author":"B Lelievre","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/AAC.48.10.4063-4066.2004","article-title":"Efficacy of posaconazole in a murine model of central nervous system aspergillosis","volume":"48","author":"JK Imai","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/phar.1172","article-title":"Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis","volume":"33","author":"EF Egelund","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jocn.2014.05.004","article-title":"Posaconazole responsive cerebral aspergillosis in an immunocompetent adult","volume":"21","author":"JR Ellenbogen","year":"2014","journal-title":"J Clin Neurosci"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/myc.12289","article-title":"Successful long-term management of invasive cerebral fungal infection following liver transplantation","volume":"58","author":"MS Patel","year":"2015","journal-title":"Mycoses"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas' disease","volume":"370","author":"I Molina","year":"2014","journal-title":"N Engl J Med"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pt.2014.11.004","article-title":"Match-making for posaconazole through systems thinking","volume":"31","author":"MA Fugi","year":"2015","journal-title":"Trends Parasitol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0035-9203(92)90298-Q","article-title":"High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire","volume":"86","author":"J Pepin","year":"1992","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole\u2014a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"E Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1128\/AAC.02754-13","article-title":"Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease","volume":"58","author":"MT Bahia","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"e0004299","DOI":"10.1371\/journal.pntd.0004299","article-title":"Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome","volume":"9","author":"DC Jones","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jmr.2412","article-title":"Dynamics of CYP51: implications for function and inhibitor design","volume":"28","author":"X Yu","year":"2015","journal-title":"J Mol Recognit"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0005328","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0005125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T14:24:59Z","timestamp":1568557499000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0005125"}},"subtitle":[],"editor":[{"given":"Jayne","family":"Raper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,17]]},"references-count":87,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0005125","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,17]]}}}